关键词

布地奈德 非酒精性脂肪性肝炎 ABCWY疫苗 西米普利单抗 单细胞多组学分析 托莱西单抗 艾贝司他 福雷芦单抗

 

#今日行业热点#

①The Lancet：Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

临床试验：布地奈德靶向释放制剂用于原发性IgA肾病患者的疗效和安全性(NefIgArd):一项Ⅲ期、多中心、随机、双盲、安慰剂对照试验

DOI: 10.1016/S0140-6736(23)01554-4

②The Lancet Gastroenterology and Hepatology：NASH drug treatment development: challenges and lessons

综述：非酒精性脂肪性肝炎（NASH）药物研发的历程、教训与挑战

DOI: 10.1016/S2468-1253(23)00159-0

③The Lancet Infectious Diseases：Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial

临床试验：五价脑膜炎球菌ABCWY疫苗在青少年和年轻人中的免疫原性和安全性：一项观察者盲、主动对照、随机试验

DOI: 10.1016/S1473-3099(23)00191-3

④The Lancet Oncology：First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

临床试验：PD-1抑制剂西米普利单抗（Cemiplimab）单药及联合化疗用于具有高PD-L1表达（TPS≥50％）、局部晚期或转移性的非小细胞肺癌（NSCLC）的随访（EMPOWER-Lung 1）：一项多中心、开放标签、随机、Ⅲ期试验

DOI: 10.1016/S1470-2045(23)00329-7

⑤The Lancet Respiratory Medicine：Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management

综述：对与肺部疾病相关的肺动脉高压的病理机制、诊断和管理的新见解

DOI: 10.1016/S2213-2600(23)00259-X

⑥Nature Immunology：Single-cell multiomic analysis of thymocyte development reveals drivers of CD4+ T cell and CD8+ T cell lineage commitment

胸腺细胞发育的单细胞多组学分析揭示CD4+ T细胞和CD8+ T细胞谱系分化的驱动因素

DOI: 10.1038/s41590-023-01584-0

⑦国产首款自主研发的抗PCSK9单克隆抗体托莱西单抗获得国家药品监督管理局批准用于原发性高胆固醇血症和混合型血脂异常的成人患者

⑧泛HDAC抑制剂艾贝司他联合替莫唑胺在美国针对复发性胶质瘤（GBM）的Ⅰ期临床首个剂量组给药和初步安全性评估进展顺利，将开始更高剂量组的患者入组

⑨靶向cadherin-6（CDH6）抗体偶联药物（ADC）CUSP06获FDA批准开展Ⅰ期临床，拟评估用于铂类难治/耐药卵巢癌和其他晚期实体瘤

⑩靶向CD3的全人源单克隆抗体福雷芦单抗（Foralumab）获FDA批准临床，用于阿尔兹海默症

科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！